{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

An observational, cross-sectional survey to understand the management paradigm of COPD as per disease severity with changing global recommendations (Global Initiative for Chronic Obstructive Lung Diseases 2024) and its relevance in the current Indian practice scenario

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif @if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. Approximately, how many patients of COPD do you see in your practice every month? *

  2. Approximately, how many patients are newly diagnosed with COPD in your practice every month? *

  3. What is the relative percentage of patients as per disease severity? *
    4. Severity Percentage
    Mild
    %
    Moderate
    %
    Severe
    %
    Overt Exacerbation
    %
  4. What is the relative percentage of patients as per disease severity as per the GOLD assessment tool, 2024? *
    5. Severity Percentage
    Category A
    %
    Category B
    %
    Category E
    %
  5. What are the common Respiratory comorbidities you observe in COPD patients in your practice? *

    6. (Asthma, Allergic Rhinitis, Pulmonary Hypertension, Chronic Mucus Hypersecretion, Chronic Rhinosinusitis, Interstitial Lung disease (ILD))

    Severity Mention the appropriate condition
    Mild
    Moderate
    Severe
    Overt Exacerbation
  6. What are the common non-respiratory comorbidities you observe in COPD patients in your practice? *

    7. (Cardiovascular disease, Deep Vein Thrombosis(DVT), Stroke, Sleep Apnea, MI, Angina)

    Severity Mention the appropriate condition
    Mild
    Moderate
    Severe
    Overt Exacerbation
  7. How many patients of COPD suffer from Chronic Mucus Hypersecretion (CMH)? *
    8. %
  8. Can you please describe the patients characteristics with CMH? *
    9. COPD GOLD Stage
    Frequency of exacerbation
    Lung infection
    Comnmon Pathogens
    Empyema
    Bronchiactasis
  9. What are the common diagnostic tests in COPD patients in your practice? *
    10. Tests Mention the appropriate condition
    Chest X-RAY
    Spirometry
    CT Chest
    Blood tests like lgE and Eosinophils
  10. What are the commonly associated risk factors for COPD in your patients? *

    11. Risk factors

  11. How many patients of COPD develop Right heart failure? *
    12. %
  12. How many patients develop Pulmonary Artery Hypertension? *
    13. %
  13. Approximately, what are the most common symptoms observed in COPD patients in your practice as per disease severity? *
    14. Severity Symptoms
    Mild
    Moderate
    Severe
    Overt Exacerbation
  14. Please let know on the investigations to be done per severity of the disease accordingly.

    15. (Chest X-ray, High-Resolution Computed Tomography{HRCT), Sputum culture sensitivity, Spirometry (mention if any other))

    Severity Mention the appropriate option
    Mild
    Moderate
    Severe
    Overt Exacerbation
  15. What are the supportive modalities of treatment that you use in your COPD patients as per severity?

    16. (Kindly mention the relative percentages if applicable)

    Mild Moderate Severe Overt Exacerbation
    Long-term Oxygen therapy (LTOT)
    %
    %
    %
    %
    Antiinfective
    %
    %
    %
    %
    Anticoagulant
    %
    %
    %
    %
    Diuretics
    %
    %
    %
    %
    Mention if any other
    %
    %
    %
    %
    Mucolytics
    %
    %
    %
    %
    Antioxidants
    %
    %
    %
    %
  16. Which is the most common dosage form used in your COPD patients based on disease severity in your practice?

    17. (Kindly mention the relative percentages if applicable)

    Mild Moderate Severe Overt Exacerbation
    Nebulizers
    %
    %
    %
    %
    MDI
    %
    %
    %
    %
    DPI
    %
    %
    %
    %
    Tablets/Capsule
    %
    %
    %
    %
    Syrup
    %
    %
    %
    %
  17. Which is the most common drug class used in your COPD patients based on disease severity in your practice?

    18. (Kindly mention the relative percentages if applicable)

    Mild Moderate Severe Overt Exacerbation
    ICS
    %
    %
    %
    %
    ICS+LABA
    %
    %
    %
    %
    ICS+LABA+LAMA
    %
    %
    %
    %
    LABA+LAMA
    %
    %
    %
    %
    SABA
    %
    %
    %
    %
    Methyl Xanthines
    %
    %
    %
    %
    PDE4 Inhibitors
    %
    %
    %
    %
    Mucolytics
    %
    %
    %
    %
    Antihistaminics
    %
    %
    %
    %
    LTRA
    %
    %
    %
    %
    %
    %
    %
    %
  18. What is the goal of the therapy as your priority while treating COPD patients based on disease severity in your practice?

    19. (Kindly mention the relative percentages if applicable)

    Mild Moderate Severe Overt Exacerbation
    Control Dyspnea
    %
    %
    %
    %
    Delay time to Exacerbation
    %
    %
    %
    %
    Attenuate Severity of Exacerbation
    %
    %
    %
    %
    Improve Health status
    %
    %
    %
    %
    Improve Exercise Capacity
    %
    %
    %
    %
  19. Which are the most common methylxanthines you use in your COPD patients based on disease severity in your practice? *

    20. (Kindly mention the relative percentages)

    Mild Moderate Severe Overt Exacerbation Mention the Reason for the preference
    Acebrophylline
    %
    %
    %
    %
    Theophylline
    %
    %
    %
    %
    Doxophylline
    %
    %
    %
    %
    TheophyIIine+Etophylline
    %
    %
    %
    %
  20. As per clinical experience, what is the major role of Acebrophylline in COPD management? *

  21. Where do you observe Acebrophylline acting as a potent & efficacious mucolytic agent?

    22. (Kindly mention the relative percentages if applicable)

    Mild Moderate Severe Overt Exacerbation
    Acebrophylline (TheophyIIine-7-Acetic acid+AmbroxoI)
    %
    %
    %
    %
    Mention your clinical experience
  22. Do you observe Acebrophylline as an add-on therapy has an advantage over other methylxanthines in patients with cardiovascular disease? *

  23. What are the non-pharmacological and supportive treatment options do you use in your practice? *

  24. How do you manage acute exacerbation of COPD? Please mention below: *
  25. What according to you is the future breakthrough drugs in the pipeline in COPD management? *
    		26.
  26. What are your thoughts on Phosphodiasterase dual inhibitors as therapy for COPD? *
    		27.
  27. What are the pros and cons of using ICS for various stages of COPD *
    		28.
  28. What are the most common challenges in treating patients with COPD? *
    		29.
  29. What are the most common challenges you face in treating patients with COPD with Chronic Mucus Hypersecretion? *
    		30.
  30. What role does antibiotics play in your practice in patients with infected COPD? *
    31. which antibiotic do you prefer
  31. What as per you is prognosis of COPD patients and factors improving patient outcome *
    		32.